Invention Grant
US07803805B2 Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
有权
Cristalline 3 - {（3R，4R）-4-甲基-3- [甲基 - （7H-吡咯并[2,3-d]嘧啶-4-基） - 氨基] - 哌啶-1-基} -3-氧代 - 丙腈单柠檬酸盐
![Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt](/docs/US/2010-09-28/US07803805B2/abs.jpg.600x600.jpg)
- Patent Title: Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt
- Patent Title (中): Cristalline 3 - {（3R，4R）-4-甲基-3- [甲基 - （7H-吡咯并[2,3-d]嘧啶-4-基） - 氨基] - 哌啶-1-基} -3-氧代 - 丙腈单柠檬酸盐
-
Application No.: US11032990Application Date: 2005-01-10
-
Publication No.: US07803805B2Publication Date: 2010-09-28
- Inventor: Mark E. Flanagan , Zheng J. Li
- Applicant: Mark E. Flanagan , Zheng J. Li
- Applicant Address: US NJ Madison
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NJ Madison
- Agent Ram W. Sabnis
- Main IPC: A61P37/06
- IPC: A61P37/06 ; A61P11/06 ; C07D487/04 ; A61K31/519
![Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt](/abs-image/US/2010/09/28/US07803805B2/abs.jpg.150x150.jpg)
Abstract:
This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3 -oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.
Public/Granted literature
- US20050159434A1 Novel crystalline compound Public/Granted day:2005-07-21
Information query
